fumagillin


Also found in: Encyclopedia, Wikipedia.

fumagillin

(fū″mă-jĭl′ĭn)
A molecule produced by fungi that prevents new blood vessel formation (“angiogenesis”), and may be useful in treating cancers.

fumagillin

an antibiotic produced by Aspergillus fumigatus. Used in bees to control the parasite, Nosema.
References in periodicals archive ?
Thrombocytopenia is the main adverse event of fumagillin therapy, occurring in up to 33% of patients (j) and raising concerns about fumagillin use in patients with hematologic disorders.
Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent.
Zafgen will present a clinical update on beloranib and Phase 1b study highlights, as well as a poster for fumagillin, a prototype methionine aminopeptidase 2 (MetAP2) inhibitor.
Fumagillin and its analogs have been used topically to treat corneal infections and orally for gastrointestinal microsporidiosis (27), but because of possible side effects, they have not been used to treat microsporidial myositis (27).
GENERAL FUMAGILLIN DESCRIPTION, COMPOSITION, INFORMATION ON INGREDIENTS, HAZARDS IDENTIFICATION, HANDLING AND STORAGE, TOXICOLOGICAL & ECOLOGICAL INFORMATION, TRANSPORT INFORMATION
E[acute accent]PPI-2458 is a novel, proprietary small molecule belonging to the fumagillin class of compounds that specifically targets the methionine aminopeptidase-2 (MetAP-2) enzyme.
PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme.
PPI-2458 is a novel, proprietary molecule based on the fumagillin class of compounds that have been shown to prevent both abnormal cell growth and the formation of new blood vessels, which contribute to aberrant tissue growth.
PPI-2458 is a novel, proprietary molecule based on the fumagillin class of compounds that have been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as anti-angiogenesis), which contribute to the growth of aberrant tissues in diseases such as cancer and Rheumatoid Arthritis (RA).
6,548,477 was issued on April 15, 2003 covering a family of fumagillin analogs, including PPI-2458.